HRP20140707T1 - KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA - Google Patents
KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA Download PDFInfo
- Publication number
- HRP20140707T1 HRP20140707T1 HRP20140707TT HRP20140707T HRP20140707T1 HR P20140707 T1 HRP20140707 T1 HR P20140707T1 HR P20140707T T HRP20140707T T HR P20140707TT HR P20140707 T HRP20140707 T HR P20140707T HR P20140707 T1 HRP20140707 T1 HR P20140707T1
- Authority
- HR
- Croatia
- Prior art keywords
- roflumilast
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- pde4
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title claims abstract 40
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims abstract 40
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract 36
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract 36
- 208000019693 Lung disease Diseases 0.000 title claims abstract 28
- 230000002757 inflammatory effect Effects 0.000 title claims abstract 28
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title claims 29
- 229960002586 roflumilast Drugs 0.000 title claims 29
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims 12
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims 12
- 229960005370 atorvastatin Drugs 0.000 title claims 12
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 title claims 10
- 229960002855 simvastatin Drugs 0.000 title claims 10
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 title claims 10
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 238000009109 curative therapy Methods 0.000 claims abstract 11
- 230000003449 preventive effect Effects 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims 42
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 16
- 239000013066 combination product Substances 0.000 claims 15
- 229940127555 combination product Drugs 0.000 claims 15
- 206010001889 Alveolitis Diseases 0.000 claims 8
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 8
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
- 208000034189 Sclerosis Diseases 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 8
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 8
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
- 201000000306 sarcoidosis Diseases 0.000 claims 8
- 239000004615 ingredient Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- ODYFGDACHPDINU-UHFFFAOYSA-N O.O.O.[Ca] Chemical compound O.O.O.[Ca] ODYFGDACHPDINU-UHFFFAOYSA-N 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (56)
1. Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
2. Kombinacijski proizvod, naznačen time, da obuhvaća sljedeće sastojke: (A) jedna količina PDE4-inhibitora, (B) jedna količina inhibitora reduktaze HMG-CoA; gdje prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća i pri čemu svaki od sastojaka (A) i (B) je formuliran za miješanje s barem jednim farmaceutskim pomoćnim sredstvom, dok je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol.
3. Garnitura, naznačena time, da obuhvaća sljedeće sastojke: (A) farmaceutska formulacija koja uključuje jednu količinu PDE4-inhibitora, u mješavini s barem jednim farmaceutskim pomoćnim sredstvom; (B) farmaceutska formulacija koja uključuje jednu količinu inhibitora reduktaze HMG-CoA, u mješavini s barem jednim farmaceutskim pomoćnim sredstvom; pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća, dok je pritom PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol.
4. Farmaceutski sastav prema zahtjevu 1, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
5. Farmaceutski sastav prema zahtjevu 1, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
6. Farmaceutski sastav prema bilo kojem zahtjevu 1, 4 ili 5, naznačen time, da inhibitor reduktaze HMG-CoA je SIMVASTATIN.
7. Kombinacijski proizvod prema zahtjevu 2, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
8. Kombinacijski proizvod prema zahtjevu 2, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
9. Kombinacijski proizvod prema bilo kojem zahtjevu 2, 7 i 8, naznačen time, da inhibitor reduktaze HMG-CoA je SIMVASTATIN.
10. Garnitura prema zahtjevu 3, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
11. Garnitura prema zahtjevu 3, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
12. Garnitura prema bilo kojem zahtjevu 3, 10 ili 11, naznačena time, da inhibitor reduktaze HMG-CoA je SIMVASTATIN.
13. Farmaceutski sastav prema bilo kojem zahtjevu 1, 4, 5 ili 6, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
14. Farmaceutski sastav prema bilo kojem zahtjevu 1, 4, 5 ili 6, naznačen time, da upalna bolest pluća je COPD.
15. Kombinacijski proizvod prema bilo kojem zahtjevu 2, 7, 8 ili 9, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
16. Kombinacijski proizvod prema bilo kojem zahtjevu 2, 7, 8 ili 9, naznačen time, da upalna bolest pluća je COPD.
17. Garnitura prema bilo kojem zahtjevu 3, 10, 11 ili 12, naznačena time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
18. Garnitura prema bilo kojem zahtjevu 3, 10, 11 ili 12, naznačena time, da upalna bolest pluća je COPD.
19. Uporaba PDE4-inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora reduktaze HMG-CoA ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka, posebno farmaceutskog sastava prema ovom izumu, za preventivno i kurativno liječenje upalne bolesti pluća, pri čemu je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol.
20. Uporaba PDE4-inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora reduktaze HMG-CoA ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za uzastopnu ili odvojenu primjenu, posebno kombinacijskog proizvoda ili garniture prema ovom izumu, za preventivno i kurativno liječenje upalne bolesti pluća, pri čemu je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol.
21. Uporaba prema bilo kojem zahtjevu 19 ili 20, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
22. Uporaba prema bilo kojem zahtjevu 19 ili 20, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
23. Uporaba prema bilo kojem zahtjevu 19, 20, 21 ili 22, naznačena time, da inhibitor reduktaze HMG-CoA je SIMVASTATIN.
24. Uporaba prema bilo kojem zahtjevu od 19 do 23, naznačena time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
25. Uporaba prema bilo kojem zahtjevu od 19 do 23, naznačena time, da upalna bolest pluća je COPD.
26. Postupak proizvodnje farmaceutskog sastava prema bilo kojem zahtjevu 1, 4, 5, 6, 13 ili 14, naznačen time, da obuhvaća miješanje PDE4-inhibitora ili njegove farmacetski prihvatljive soli s inhibitorom reduktaze HMG-CoA ili s njegovom farmaceutski prihvatljivom soli.
27. Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
28. Kombinacijski proizvod, naznačen time, da obuhvaća sljedeće sastojke: (A) jedna količina PDE4-inhibitora, (B) jedna količina inhibitora reduktaze HMG-CoA; gdje prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća i pri čemu svaki od sastojaka (A) i (B) je formuliran za miješanje s barem jednim farmaceutskim pomoćnim sredstvom, dok je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol.
29. Garnitura, naznačena time, da obuhvaća sljedeće sastojke: (A) farmaceutska formulacija koja uključuje jednu količinu PDE4-inhibitora, u mješavini s barem jednim farmaceutskim pomoćnim sredstvom; (B) farmaceutska formulacija koja uključuje jednu količinu inhibitora reduktaze HMG-CoA, u mješavini s barem jednim farmaceutskim pomoćnim sredstvom; pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća, dok je pritom PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol.
30. Farmaceutski sastav prema zahtjevu 27, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
31. Farmaceutski sastav prema zahtjevu 27, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
32. Farmaceutski sastav prema bilo kojem zahtjevu 27, 30 ili 31, naznačen time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN.
33. Farmaceutski sastav prema bilo kojem zahtjevu 27, 30 ili 31, naznačen time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN-hemi-kalcij-seskvi-hidrat.
34. Kombinacijski proizvod prema zahtjevu 28, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
35. Kombinacijski proizvod prema zahtjevu 28, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
36. Kombinacijski proizvod prema bilo kojem zahtjevu 28, 34 i 35, naznačen time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN.
37. Kombinacijski proizvod prema bilo kojem zahtjevu 28, 34 i 35, naznačen time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN-hemi-kalcij-seskvi-hidrat.
38. Garnitura prema zahtjevu 29, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
39. Garnitura prema zahtjevu 29, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
40. Garnitura prema bilo kojem zahtjevu 29, 38 ili 39, naznačena time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN.
41. Garnitura prema bilo kojem zahtjevu 29, 38 ili 39, naznačena time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN-hemi-kalcij-seskvi-hidrat.
42. Farmaceutski sastav prema bilo kojem zahtjevu 27, 30, 31, 32 ili 33, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
43. Farmaceutski sastav prema bilo kojem zahtjevu 27, 30, 31, 32 ili 33, naznačen time, da upalna bolest pluća je COPD.
44. Kombinacijski proizvod prema bilo kojem zahtjevu 28, 34, 35, 36 ili 37, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
45. Kombinacijski proizvod prema bilo kojem zahtjevu 28, 34, 35, 36 ili 37, naznačen time, da upalna bolest pluća je COPD.
46. Garnitura prema bilo kojem zahtjevu 29, 38, 39, 40 ili 41, naznačena time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
47. Garnitura prema bilo kojem zahtjevu 29, 38, 39, 40 ili 41, naznačena time, da upalna bolest pluća je COPD.
48. Uporaba PDE4-inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora reduktaze HMG-CoA ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka, posebno farmaceutskog sastava prema ovom izumu, za preventivno i kurativno liječenje upalne bolesti pluća, pri čemu je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol.
49. Uporaba PDE4-inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora reduktaze HMG-CoA ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za uzastopnu ili odvojenu primjenu, posebno kombinacijskog proizvoda ili garniture prema ovom izumu, za preventivno i kurativno liječenje upalne bolesti pluća, pri čemu je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol.
50. Uporaba prema bilo kojem zahtjevu 48 ili 49, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
51. Uporaba prema bilo kojem zahtjevu 48 ili 49, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
52. Uporaba prema bilo kojem zahtjevu 48, 49, 50 ili 51, naznačena time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN.
53. Uporaba prema bilo kojem zahtjevu 48, 49, 50 ili 51, naznačena time, da inhibitor reduktaze HMG-CoA je ATORVASTATIN-hemi-kalcij-seskvi-hidrat.
54. Uporaba prema bilo kojem zahtjevu od 48 do 53, naznačena time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
55. Uporaba prema bilo kojem zahtjevu od 48 do 53, naznačena time, da upalna bolest pluća je COPD.
56. Postupak proizvodnje farmaceutskog sastava prema bilo kojem zahtjevu 27, 30, 31, 32, 33, 42 ili 43, naznačen time, da obuhvaća miješanje PDE4-inhibitora ili njegove farmaceutski prihvatljive soli s inhibitorom reduktaze HMG-CoA ili s njegovom farmaceutski prihvatljivom soli.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06116625 | 2006-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140707T1 true HRP20140707T1 (hr) | 2014-09-12 |
Family
ID=37311957
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140073TT HRP20140073T1 (hr) | 2006-07-05 | 2014-01-21 | Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti |
HRP20140707TT HRP20140707T1 (hr) | 2006-07-05 | 2014-07-22 | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140073TT HRP20140073T1 (hr) | 2006-07-05 | 2014-01-21 | Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti |
Country Status (26)
Country | Link |
---|---|
US (2) | US20100069392A1 (hr) |
EP (3) | EP2040707B1 (hr) |
JP (3) | JP5349302B2 (hr) |
KR (1) | KR101433394B1 (hr) |
CN (3) | CN101484166B (hr) |
AT (1) | ATE535244T1 (hr) |
AU (1) | AU2007271186C1 (hr) |
BR (1) | BRPI0713768A2 (hr) |
CA (1) | CA2656366A1 (hr) |
CY (2) | CY1114742T1 (hr) |
DK (2) | DK2359826T3 (hr) |
EA (2) | EA032476B1 (hr) |
ES (3) | ES2378281T3 (hr) |
HR (2) | HRP20140073T1 (hr) |
IL (3) | IL195433A (hr) |
ME (2) | ME01901B (hr) |
MX (1) | MX2008016123A (hr) |
NO (1) | NO342590B1 (hr) |
NZ (3) | NZ594369A (hr) |
PL (2) | PL2363130T3 (hr) |
PT (2) | PT2363130E (hr) |
RS (2) | RS53084B (hr) |
SI (2) | SI2359826T1 (hr) |
UA (3) | UA101556C2 (hr) |
WO (1) | WO2008003701A2 (hr) |
ZA (1) | ZA200809905B (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587591A (en) * | 2008-03-14 | 2012-10-26 | Otsuka Pharma Co Ltd | Diarylthiazole derivatives such as tetomilast as mmp-2 and/or mmp-9 inhibitors |
CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
JP6755240B2 (ja) * | 2014-06-05 | 2020-09-16 | トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法 |
EP3152329A2 (en) | 2014-06-05 | 2017-04-12 | Transregion-International Institute For Translational Medicine Gmbh | Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers |
WO2015185656A1 (en) * | 2014-06-05 | 2015-12-10 | Medizinische Universität Wien | Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021218988A1 (zh) * | 2020-04-30 | 2021-11-04 | 中国科学院上海药物研究所 | Prdx1激动剂及其用途 |
US20240042147A1 (en) * | 2022-08-03 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Dry powder inhaler |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU535944B2 (en) | 1979-06-15 | 1984-04-12 | Merck & Co., Inc. | Hypocholestermic fermentation products from aspergillus |
AU548996B2 (en) | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
WO1984002131A1 (en) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
EP0307342B1 (de) | 1987-07-10 | 1996-01-03 | Hoechst Aktiengesellschaft | 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US4863957A (en) | 1987-12-21 | 1989-09-05 | Rorer Pharmaceutical Corporation | Novel HMG-CoA reductase inhibitors |
FR2642065B1 (fr) | 1989-01-24 | 1991-05-24 | Lipha | Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant |
JP2829451B2 (ja) | 1990-11-30 | 1998-11-25 | 大塚製薬株式会社 | 活性酸素抑制剤 |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993019749A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
RO115872B1 (ro) * | 1992-04-02 | 2000-07-28 | Smithkline Beecham Corp | Derivati substituiti ai acidului fenilcarboxilic si compozitie farmaceutica ce ii contine |
DK0706513T3 (da) | 1993-07-02 | 2002-09-09 | Altana Pharma Ag | Fluoralkoxysubstituerede benzamider og anvendelse deraf som cyklisk-nukleotid phosphodiesteraseinhibitorer |
GB9504460D0 (en) | 1995-03-06 | 1995-04-26 | Bayer Ag | N-(3-Benzofuranyl)urea-derivatives |
DK0837860T3 (da) | 1995-06-06 | 2002-05-27 | Pfizer | Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner |
DE19636150A1 (de) | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
ES2262072T3 (es) | 1998-04-28 | 2006-11-16 | Elbion Ag | Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4. |
US20010006656A1 (en) | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
DE19944161A1 (de) | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
US6410563B1 (en) * | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
MY134008A (en) | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
JP2001294526A (ja) * | 2000-02-10 | 2001-10-23 | Takeda Chem Ind Ltd | TNF−α抑制剤 |
US20030018040A1 (en) | 2000-02-10 | 2003-01-23 | Yasuo Sugiyama | Tnf-alpha inhibitors |
MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
US20050102317A1 (en) * | 2000-07-21 | 2005-05-12 | Ali Kamarei | System and method for event calendaring using a customizable rules subset |
AU2002210521A1 (en) | 2000-09-19 | 2002-04-02 | Novimmune S.A. | Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
AU2002234634B2 (en) * | 2001-02-15 | 2007-07-26 | Takeda Gmbh | Phthalayinone-piperidino-derivatives as PDE4 inhibitors |
IL157734A0 (en) * | 2001-03-06 | 2004-03-28 | Cellegy Pharma Inc | Pharmaceutical compositions for the treatment of urogenital disorders |
JP4193435B2 (ja) * | 2002-07-23 | 2008-12-10 | ブラザー工業株式会社 | インクカートリッジ、および、そのインク充填方法 |
DE60205899T2 (de) * | 2001-05-24 | 2006-06-29 | Merck Frosst Canada & Co, Kirkland | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren |
DE60204463T2 (de) * | 2001-06-27 | 2006-05-18 | Merck Frosst Canada & Co, Kirkland | Substituierte 8-Arylchinoline als PDE4-Hemmer |
US20030114469A1 (en) | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
JP2005538972A (ja) * | 2002-07-02 | 2005-12-22 | メルク フロスト カナダ アンド カンパニー | ジアリール置換エタンピリドンpde4阻害剤 |
MXPA05005161A (es) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida. |
IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
BR0316451A (pt) * | 2002-11-27 | 2005-10-11 | Altana Pharma Ag | Combinação sinergìstica compreendendo roflumilast e formoterol |
US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
WO2004091626A1 (en) * | 2003-04-07 | 2004-10-28 | Osteoscreen, Inc. | Bone growth stimulation with no/statin and other no modulating combinations |
KR20060017494A (ko) | 2003-04-11 | 2006-02-23 | 그렌마크 파머수티칼스 에스. 아. | 염증 및 알레르기성 질환 치료용으로 유용한 신규 헤테로사이클릭 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물 |
EP1635829A1 (en) * | 2003-04-30 | 2006-03-22 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors |
WO2004098578A2 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 |
AU2004241749B2 (en) * | 2003-05-22 | 2010-03-25 | Takeda Gmbh | Composition comprising a PDE4 inhibitor and a PDE5 inhibitor |
US20060160834A1 (en) * | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
US20060148721A1 (en) * | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
DE10348646A1 (de) | 2003-10-15 | 2005-05-25 | Gkn Driveline International Gmbh | Rollbalg mit großem Krümmungsradius |
AU2005235306B2 (en) * | 2004-04-19 | 2008-08-21 | Loma Linda University | Composition and method of decreasing renal ischemic damage |
CA2563377A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
GB0415789D0 (en) * | 2004-07-15 | 2004-08-18 | Astrazeneca Ab | Novel combination |
DE102004046236A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
GB0508924D0 (en) | 2005-04-30 | 2005-06-08 | Astrazeneca Ab | New use |
GB0510207D0 (en) | 2005-05-19 | 2005-06-22 | Astrazeneca Ab | Novel combination |
ES2362534T3 (es) | 2005-06-08 | 2011-07-07 | Kowa Company, Ltd. | Nuevo agente reductor de los triglicéridos. |
EP2377530A3 (en) * | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
AR057555A1 (es) * | 2005-10-27 | 2007-12-05 | Merck Frosst Canada Ltd | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo |
WO2007054896A1 (en) | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
WO2008036846A2 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
-
2007
- 2007-07-03 CN CN2007800252405A patent/CN101484166B/zh not_active Expired - Fee Related
- 2007-07-03 PT PT111645180T patent/PT2363130E/pt unknown
- 2007-07-03 AU AU2007271186A patent/AU2007271186C1/en not_active Ceased
- 2007-07-03 UA UAA201111256A patent/UA101556C2/uk unknown
- 2007-07-03 PL PL11164518T patent/PL2363130T3/pl unknown
- 2007-07-03 RS RS20130560A patent/RS53084B/en unknown
- 2007-07-03 CN CN2012102488576A patent/CN102772411A/zh active Pending
- 2007-07-03 US US12/308,878 patent/US20100069392A1/en not_active Abandoned
- 2007-07-03 SI SI200731395T patent/SI2359826T1/sl unknown
- 2007-07-03 NZ NZ594369A patent/NZ594369A/xx not_active IP Right Cessation
- 2007-07-03 PL PL11164516T patent/PL2359826T3/pl unknown
- 2007-07-03 EP EP07787007A patent/EP2040707B1/en active Active
- 2007-07-03 EA EA201401042A patent/EA032476B1/ru not_active IP Right Cessation
- 2007-07-03 UA UAA200900759A patent/UA98466C2/uk unknown
- 2007-07-03 RS RS20140402A patent/RS53461B/en unknown
- 2007-07-03 CN CN2012102495122A patent/CN102764440A/zh active Pending
- 2007-07-03 CA CA002656366A patent/CA2656366A1/en not_active Abandoned
- 2007-07-03 EA EA200900073A patent/EA021461B1/ru not_active IP Right Cessation
- 2007-07-03 BR BRPI0713768-0A patent/BRPI0713768A2/pt not_active Application Discontinuation
- 2007-07-03 EP EP11164516.4A patent/EP2359826B1/en active Active
- 2007-07-03 DK DK11164516.4T patent/DK2359826T3/da active
- 2007-07-03 MX MX2008016123A patent/MX2008016123A/es active IP Right Grant
- 2007-07-03 NZ NZ573378A patent/NZ573378A/en not_active IP Right Cessation
- 2007-07-03 ES ES07787007T patent/ES2378281T3/es active Active
- 2007-07-03 ES ES11164516.4T patent/ES2443342T3/es active Active
- 2007-07-03 KR KR1020097001868A patent/KR101433394B1/ko active IP Right Grant
- 2007-07-03 DK DK11164518.0T patent/DK2363130T3/da active
- 2007-07-03 PT PT111645164T patent/PT2359826E/pt unknown
- 2007-07-03 WO PCT/EP2007/056683 patent/WO2008003701A2/en active Application Filing
- 2007-07-03 ES ES11164518.0T patent/ES2489265T3/es active Active
- 2007-07-03 AT AT07787007T patent/ATE535244T1/de active
- 2007-07-03 UA UAA201212837A patent/UA106422C2/uk unknown
- 2007-07-03 SI SI200731492T patent/SI2363130T1/sl unknown
- 2007-07-03 ME MEP-2014-91A patent/ME01901B/me unknown
- 2007-07-03 EP EP11164518.0A patent/EP2363130B1/en active Active
- 2007-07-03 NZ NZ603207A patent/NZ603207A/en not_active IP Right Cessation
- 2007-07-03 JP JP2009517256A patent/JP5349302B2/ja not_active Expired - Fee Related
- 2007-07-03 ME MEP-2014-9A patent/ME01648B/me unknown
-
2008
- 2008-11-20 ZA ZA200809905A patent/ZA200809905B/xx unknown
- 2008-11-23 IL IL195433A patent/IL195433A/en active IP Right Grant
-
2009
- 2009-01-27 NO NO20090370A patent/NO342590B1/no not_active IP Right Cessation
-
2012
- 2012-08-05 IL IL221309A patent/IL221309A/en active IP Right Grant
- 2012-08-05 IL IL221307A patent/IL221307A/en active IP Right Grant
- 2012-10-11 JP JP2012225891A patent/JP2013035870A/ja active Pending
- 2012-10-11 JP JP2012225892A patent/JP2013035871A/ja active Pending
-
2014
- 2014-01-07 CY CY20141100008T patent/CY1114742T1/el unknown
- 2014-01-21 HR HRP20140073TT patent/HRP20140073T1/hr unknown
- 2014-07-22 HR HRP20140707TT patent/HRP20140707T1/hr unknown
- 2014-08-07 CY CY20141100621T patent/CY1115462T1/el unknown
-
2015
- 2015-05-22 US US14/719,948 patent/US9713614B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
WO2007005668A3 (en) | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer | |
NZ600790A (en) | Combination therapy for copd | |
UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
WO2008064321A3 (en) | Methods of treating chronic inflammatory diseases using a gm-csf antagonist | |
WO2006089005A3 (en) | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors | |
WO2011030351A3 (en) | Taste - masked pharmaceutical compositions | |
GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
WO2009109618A3 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
WO2007099553A3 (en) | 1,3-dioxane carboxylic acids | |
WO2009109616A8 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 | |
WO2005061467A3 (en) | Piperazine derivatives as bradykinin antagonists | |
WO2006129237A3 (en) | Novel piperidine carboxylic acid amide derivatives | |
WO2009109654A3 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40 | |
WO2005079766A3 (en) | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds | |
WO2005041864A3 (en) | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method | |
WO2005112914A3 (en) | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
ATE542525T1 (de) | Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung | |
WO2006021401A3 (en) | Bicylononene derivatives | |
PH12018502522A1 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
WO2005120148A3 (en) | Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases |